{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.28","spread":"1.28","upperLimit":"8.87","value":"2.69"},{"groupId":"OG001","lowerLimit":"1.15","spread":"1.15","upperLimit":"2.79","value":"1.35"},{"groupId":"OG002","lowerLimit":"1.38","spread":"1.38","upperLimit":"8.84","value":"6.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"PFS was defined as the time from date of first dose to the date of disease progression (PD). PFS was assessed based on the investigators' assessments utilizing RECIST 1.1. PD was defined as at least 20% increase or 5 mm increase in the sum of diameters of target lesions recorded since the treatment started or the appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with RMS received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG000","title":"Phase 2: RMS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants with NRSTS received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of unacceptable toxicity or withdrawal of consent.","id":"OG001","title":"Phase 2: NRSTS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants with EWS received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and Irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of unacceptable toxicity or withdrawal of consent.","id":"OG002","title":"Phase 2: EWS Cohort, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all participants who received at least 1 dose of either study drug.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of first documentation of PD, or date of death, whichever occurred first up to approximately 2 years 4 months","title":"Phase 2: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}